Outcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases

被引：1
|
作者：
Carey, Patricia [1 ]
Pardanani, Animesh [2 ]
Starlinger, Patrick [3 ]
Tefferi, Ayalew [2 ]
Gangat, Naseema [2 ]
机构：
[1] Mayo Clin, Div Internal Med, Rochester, MN USA
[2] Mayo Clin, Dept Med, Div Hematol, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Surg, Div Hepatobiliary Surg, Rochester, MN USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2025年 / 100卷 / 03期
关键词：
JAK2; myeloproliferative; thrombosis; transplant; AVAILABLE THERAPY; COMFORT-II; RUXOLITINIB; SURVIVAL; PHASE-3;
D O I：
10.1002/ajh.27570
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：527 / 530
页数：4
相关论文
共 13 条
  • [1] Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman, Guido
    Mascarenhas, John
    EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (01) : 23 - 28
  • [2] Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis
    Mascarenhas, John
    Baer, Maria R.
    Kessler, Craig
    Hexner, Elizabeth
    Tremblay, Douglas
    Price, Leah
    Sandy, Lonette
    Weinberg, Rona
    Pahl, Heike
    Silverman, Lewis R.
    Goldberg, Judith D.
    Kosiorek, Heidi
    Dueck, Amylou C.
    Hoffman, Ronald
    LEUKEMIA & LYMPHOMA, 2019, 60 (05) : 1343 - 1345
  • [3] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
    Jaekel, N.
    Behre, G.
    Behning, A.
    Wickenhauser, C.
    Lange, T.
    Niederwieser, D.
    Al-Ali, H. K.
    BONE MARROW TRANSPLANTATION, 2014, 49 (02) : 179 - 184
  • [4] Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
    N Jaekel
    G Behre
    A Behning
    C Wickenhauser
    T Lange
    D Niederwieser
    H K Al-Ali
    Bone Marrow Transplantation, 2014, 49 : 179 - 184
  • [5] Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
    Tremblay, Douglas
    Dougherty, Mikaela
    Mascarenhas, John
    Gallagher, Emily Jane
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [6] Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
    Komrokji, Rami S.
    Seymour, John F.
    Roberts, Andrew W.
    Wadleigh, Martha
    To, L. Bik
    Scherber, Robyn
    Turba, Elyce
    Dorr, Andrew
    Zhu, Joy
    Wang, Lixia
    Granston, Tanya
    Campbell, Mary S.
    Mesa, Ruben A.
    BLOOD, 2015, 125 (17) : 2649 - 2655
  • [7] Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy
    Handa, Shivani
    Sivakumar, Ganesh
    Srisuwananukorn, Andrew
    Dueck, Amylou
    Tremblay, Douglas
    Mascarenhas, John
    Ginzburg, Yelena
    Kremyanskaya, Marina
    Hoffman, Ronald
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09) : e314 - e319
  • [8] Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
    Harrison, Claire N.
    Schaap, Nicolaas
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Zweegman, Sonja
    Talpaz, Moshe
    Verstovsek, Srdan
    Rose, Shelonitda
    Zhang, Jun
    Sy, Oumar
    Mesa, Ruben A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 317 - 327
  • [9] Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS-911543 JAK2 inhibitor
    Gangat, Naseema
    Begna, Kebede H.
    Al-Kali, Aref
    Hogan, William
    Litzow, Mark
    Pardanani, Animesh
    Tefferi, Ayalew
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [10] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    Verstovsek, S.
    Talpaz, M.
    Ritchie, E.
    Wadleigh, M.
    Odenike, O.
    Jamieson, C.
    Stein, B.
    Uno, T.
    Mesa, R. A.
    LEUKEMIA, 2017, 31 (02) : 393 - 402
12